PharmaCyte Biotech Inc. (PMCB) recent quarterly performance of 12.87% is not showing the real picture


PharmaCyte Biotech Inc. (NASDAQ: PMCB) established initial surge of 2.33% at $3.07, as the Stock market unbolted on November 23, 2022. During the day, the stock rose to $3.09 and sunk to $2.99 before settling in for the price of $3.00 at the close. Taking a more long-term approach, PMCB posted a 52-week range of $1.79-$3.10.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Meanwhile, its Annual Earning per share during the time was 48.90%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 88.90%. This publicly-traded company’s shares outstanding now amounts to $20.83 million, simultaneously with a float of $19.87 million. The organization now has a market capitalization sitting at $63.49 million. At the time of writing, stock’s 50-day Moving Average stood at $2.76, while the 200-day Moving Average is $2.42.

PharmaCyte Biotech Inc. (PMCB) Ownership Facts and Figures

Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the PharmaCyte Biotech Inc. industry. PharmaCyte Biotech Inc.’s current insider ownership accounts for 0.20%, in contrast to 30.40% institutional ownership.

PharmaCyte Biotech Inc. (PMCB) Earnings and Revenue Records

Going through the last 3-months fiscal report unveiled on the 7/30/2022, it has been observed that the corporation posted -$0.07 earnings per share (EPS) during the time that was better the consensus figure (set at -$0.07) by $0. This company achieved a return on equity of -8.78. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.

PharmaCyte Biotech Inc.’s EPS increase for this current 12-month fiscal period is 88.90% and is forecasted to reach -0.38 in the upcoming year.

PharmaCyte Biotech Inc. (NASDAQ: PMCB) Trading Performance Indicators

Let’s observe the current performance indicators for PharmaCyte Biotech Inc. (PMCB). It’s Quick Ratio in the last reported quarter now stands at 75.50. The Stock has managed to achieve an average true range (ATR) of 0.13.

In the same vein, PMCB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.23, a figure that is expected to reach -0.08 in the next quarter, and analysts are predicting that it will be -0.38 at the market close of one year from today.

Technical Analysis of PharmaCyte Biotech Inc. (PMCB)

Now, what If we examine the latest scores posted by [PharmaCyte Biotech Inc., PMCB]. During the last 5-days, its volume was lower the volume of 0.25 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 60.26% While, its Average True Range was 0.12.


Please enter your comment!
Please enter your name here